Skip to main content
S&P 5007,659.44-1.09%DOW52,002.41-0.34%NASDAQ26,140.03-2.14%BTC$82,170.00+0.19%ETH$2,415.39-0.07%GOLD$4,195.30+0.34%OIL$98.32-0.71%
Smart Investors Daily
SID Premium
PF

NASDAQ · PFSA

Profusa, Inc. Common Stock

Healthcare · Medical - Equipment & Services

$0.93

Down-$0.14 (-12.98%)

Updated Oct 19, 2026, 10:41 AM

SID Score

3.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
7.48M
P/E ratio
-0.14
Dividend yield
0.00%
52-week range
$0.10 – $28.32
Volume
143.01K
Avg. volume
12.57M

Price performance · PFSA

PFSA price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 16, 2026

PFSA closed at $0.93 after 20 trading sessions, down 52.01% for the selected period.

Last close
$0.93
Period change
-52.01%
Period low
$0.93
Period high
$3.03
Daily close
View OHLC price history
PFSA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 16, 2026$1.02$1.0267$0.931$0.9311143.01K
Oct 15, 2026$1.06$1.08$0.91$1.073.47M
Oct 14, 2026$1.25$1.45$1.18$1.28629.39K
Oct 13, 2026$1.28$1.31$1.23$1.2899.09K
Oct 12, 2026$1.36$1.4032$1.25$1.30265.96K
Oct 9, 2026$1.42$1.53$1.40$1.42235.56K
Oct 8, 2026$1.53$1.65$1.45$1.49818.96K
Oct 7, 2026$1.62$1.68$1.42$1.50424.23K
Oct 6, 2026$1.72$1.7292$1.60$1.66266.24K
Oct 5, 2026$1.71$1.76$1.61$1.75285.77K
Oct 2, 2026$1.83$1.8331$1.6701$1.69372.27K
Oct 1, 2026$1.90$1.95$1.70$1.87584.12K
Sep 30, 2026$1.99$2.29$1.881$1.981.27M
Sep 29, 2026$1.66$2.45$1.631$2.2710.95M
Sep 28, 2026$1.98$2.02$1.69$1.69824.88K
Sep 25, 2026$2.70$2.75$2.10$2.182.54M
Sep 24, 2026$3.51$4.18$2.39$3.0379.27M
Sep 23, 2026$1.88$2.38$1.8622$2.051.86M
Sep 22, 2026$1.89$2.23$1.85$2.174.05M
Sep 21, 2026$1.87$2.00$1.8212$1.9454.78K

Latest PFSA news

The latest Smart Investors Daily articles mentioning PFSA.

Stock researchCompany · Overview

PFSA research

Overview

Company profile and research snapshot.

Company profile

Profusa Inc is a clinical-stage digital health and medical technology company focused on developing biosensing solutions to improve health outcomes for patients with a variety of different diseases and conditions. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 15, 2026

Profusa Receives ISO 13485:2016 Certificate from GMED

Providing a Foundational Quality Management System (QMS) for Commercialization Certificate issued by GMED, an EU MDR notified body, following the positive certification decision previously announcedISO 13485 certification supports ongoing MDR conformity assessment activities for the Lumee Oxygen Platform and represents an important milestone toward MDR certification and CE marking. BERKELEY, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA) ("Profusa" or the "Company"), a di

Yahoo · Sep 24, 2026

Profusa ISO 13485 Certification Decision Advances Lumee Oxygen Platform Toward CE Mark

Profusa received a positive decision from GMED on ISO 13485 certification, expected in early October, while additional European MDR conformity assessment work remains before the Lumee Oxygen Platform can receive a CE mark. Key Investor TakeawaysProfusa (NASDAQ:PFSA) received a positive decision from notified body GMED regarding certification of its quality management system to ISO 13485.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By